Lok Sabha Question No. 4561 (UNSTARRED), answered on 2022-03-30
Subject: Imports of Pharmaceutical Products
Ministry: COMMERCE AND INDUSTRY
Asked by: Pratima Mondal

## GOVERNMENT OF INDIA MINISTRY OF COMMERCE & INDUSTRY (DEPARTMENT OF COMMERCE)

## LOK SABHA UNSTARRED QUESTION NO. 4561 TO BE ANSWERED ON 30 th  MARCH, 2022

## IMPORTS OF PHARMACEUTICAL PRODUCTS

## 4561.         SHRIMATI PRATIMA MONDAL:

Will the Minister of COMMERCE & INDUSTRY ( वाणिज्य एवं उद्योग मंत्री ) be pleased to state:

- (a) the details of imports of pharmaceutical products during each of the last three years, country wise;
- (b) whether  India is  heavily  dependent  on  China  for  drug  imports  and  if  so,  the  details thereof;
- (c) whether the Government proposes to set up specified pharmaceutical zones in order to reduce the country's dependence on import; and
- (d) if so, the details thereof along with the time by which these pharma zones are likely to be set up?

## ANSWER

okf.kT; ,oa m|ksx ea=ky; esa jkT; ea=h ¼Jherh vuqfiz;k iVsy½

## THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE AND INDUSTRY (SMT. ANUPRIYA PATEL)

## (a) :   Import of pharmaceutical products during the last three years is as follows:

| Values in USD Million   |   Values in USD Million |
|-------------------------|-------------------------|
| 2018-19                 |                    6359 |
| 2019-20                 |                    6460 |
| 2020-21                 |                    6975 |

Source: DGCI&S

Country-wise details of import of pharmaceutical products is given at Annexure -I .

(b):  India imports bulk drugs and drug intermediates from China in the form of raw materials as  well as finished products for both domestic consumption and exports.

(c  )  &  (d):    In  order  to  make  the  country  Atmanirbhar  in  pharmaceuticals,  the  Department  of Pharmaceuticals has launched the following four schemes for promoting domestic manufacturing of

Pharmaceutical drugs including bulk drugs by attracting large investments in the sector to ensure their sustainable domestic supply and thereby reduce India's import dependence on other countries:

- (I)   Under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of  critical  Key  Starting  Materials  (KSMs)/  Drug  Intermediates  (DIs)  and  Active  Pharmaceutical Ingredients (APIs) in India, financial incentive is given for manufacturing of 41 KSMs/ DIs and APIs. The total financial outlay of the scheme is Rs. 6,940 crore and the tenure of the scheme is from FY 2020-2021 to 2029-30.
- (II)     The Scheme for Promotion of Bulk Drug Parks provides for grant-in-aid to 3 Bulk Drug Parks for creation of Common Infrastructure Facilities (CIF) with a maximum limit of Rs.1000 crore per park or 70% of the project cost of CIF, whichever is less. In case of North Eastern States and Hilly States (Himachal  Pradesh,  Uttarakhand,  Union  Territory  of  Jammu  &  Kashmir  and  Union  Territory  of Ladakh), financial assistance is 90% of the project cost. The total financial outlay of the Scheme is Rs. 3000 crore and the tenure of the Scheme is from FY 2020-21 to 2024-25.
- (III)     The objective of the Production Linked Incentive Scheme for Pharmaceuticals is to enhance India's manufacturing capabilities by increasing investment and production in the sector and contribute to product diversification to high value goods in the pharmaceutical sector, and also to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains. The total financial outlay of the scheme is Rs. 15,000 crore and the tenure of the scheme is from FY 2020-2021 to 2028-29.
- (IV)    The objective of Strengthening of Pharmaceutical Industry (SPI) Scheme is to strengthen the existing infrastructure facilities in order to make India a global leader in the Pharma sector. The scheme consists  of  three  components/sub-schemes,  of  which  one  of  the  components  is  "Assistance  to Pharmaceutical Industry for Common Facilities (APICF)" the objective of which is to strengthen the existing  pharmaceutical  clusters'  capacity  for  their  sustained  growth  by  creating  tangible  assets  as 'Common Facilities'.  The  illustrative  list  of  eligible  activities  under  this  sub-scheme  in  order  of priority are R&D Labs, Testing Laboratories for Pharma Products, Effluent Treatment Plants, Logistic Centres and Training Centres. The total financial outlay of the Scheme is Rs.500 Crore and the tenure of the Scheme is from FY 2021-22 to FY 2025-26.

******

## Statement referred to in reply of part (a) of Lok Sabha Unstarred question no. 4561 for answer on 30 th  March 2022.

## The import of pharmaceutical products in terms of value from top 25 countries during 2018-19 to 2020-21

(Values in USD Million)

|   S.No. | Country         |   2018-19 |   2019-20 |   2020-21 |
|---------|-----------------|-----------|-----------|-----------|
|       1 | China P Rp      |    2630.6 |    2562.8 |    2903.4 |
|       2 | U S A           |     630   |     631.1 |     564.4 |
|       3 | Belgium         |     308.2 |     358.2 |     380.4 |
|       4 | Switzerland     |     349.6 |     354.5 |     394   |
|       5 | Germany         |     335   |     319.1 |     275.6 |
|       6 | U K             |     119   |     126   |     120.6 |
|       7 | Singapore       |     211.7 |     210.2 |     191.6 |
|       8 | Spain           |      84.2 |      97.6 |     118.9 |
|       9 | Netherland      |     168.6 |     172   |     173.4 |
|      10 | Italy           |     204.4 |     220.6 |     186.9 |
|      11 | France          |     202.5 |     205.1 |     231.1 |
|      12 | Denmark         |     108   |     129.4 |     131.9 |
|      13 | Korea Rp        |      97   |      99.4 |     339   |
|      14 | Japan           |      92.3 |     112.6 |      94.3 |
|      15 | Indonesia       |     100.8 |     127.9 |      89.2 |
|      16 | Russia          |       3.7 |       6.4 |       6.7 |
|      17 | Austria         |      36   |      53.8 |      66.5 |
|      18 | Hong Kong       |      89   |      61.5 |      77.4 |
|      19 | Brazil          |      67.7 |      87.9 |      91.8 |
|      20 | Ireland         |      57.2 |      60.9 |      56.2 |
|      21 | Taiwan          |      39.7 |      42.2 |      46.7 |
|      22 | Slovenia        |      28.2 |      41.1 |      60.6 |
|      23 | Sweden          |      14.1 |      22.6 |      19   |
|      24 | Malaysia        |      31.8 |      33.5 |      29.9 |
|      25 | Vietnam Soc Rep |      18.2 |      22.5 |      34.5 |

Source: DGCI&S * Provisional

*******